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Stlmmary 
Major histocompatibility  complex (MHC) class II deficiency is an inherited autosomal recessive 
combined immunodeficiency. The disease is known as bare lymphocyte syndrome (BLS). BLS 
is characterized by a lack of constitutive MHC class II expression on macrophages and B cells 
as well as a lack of induced MHC class II expression on cells other than professional antigen- 
presenting cells (APCs) due to the absence of mRNA and protein of the human leukocyte antigen 
(HLA) class II molecules, designated HLA-DR, -DO~ and -DP. The defect in gene expression 
is located at the transcriptional  level and affects all class II genes simultaneously. Here we have 
analyzed transcription  and protein expression of class II antigens in Epstein-Barr virus (EBV)- 
transformed B lymphoblastoid cell lines and mononuclear cells (MNCs) of twin brothers. Whereas 
flow cytometric analysis failed to detect class II antigens on the cell surface of the patients' EBV-B 
cells and MNCs, examination of the genes coding for HLA-DR, -DQ, -DP, and the invariant 
chain (Ii) by reverse transcriptase-polymerase chain reaction amplification resulted in an unusual 
mRNA pattern in the B cell lines of the patients  (HLA-DRa §  -DtLS-, -DQo~  +, -DQ~-, 
-DPol-, -DP~ +, Ii+).  In accordance with these findings no HLA-DRB-specific  protein was 
detected by immunoblotting, whereas low levels of HLA-DRo~ and normal levels of Ii were 
present. In contrast to EBV-B cells, the MNCs of both patients displayed a residual HLA-DILS, 
-DOff, and -DPol mRNA signal. Furthermore, HLA-DRB-specific protein was found in addition 
to HLA-DRc~ by immunoblotting of cell lysates, even  though it was dearly decreased  as compared 
with controls. Our results indicate that the defect in class II antigen expression is not necessarily 
present to the same extent in B cells and cells of other lineages, mRNA levels of HLA-DtL8 
were found to be enriched in adherent cells within the MNC fraction.  Further investigations 
indicated that the MHC class II expressed is functional in antigen presentation, as the two boys' 
CD4 + T  cells became activated and expressed interleukin-2R after stimulation  of peripheral 
blood mononuclear cell cultures with recall antigen (tetanus toxoid). Furthermore, T cells tested 
in one of the two patients responded to both MHC class I and II allostimulation, and this response 
was inhibited by monoclonal antibodies of the respective  specificity.  Whereas the MNC population 
contained  sufficient APCs to activate CD4 + T  cells in response to antigenic  stimulation,  the 
patients'  EBV-B cells were unable to present recall antigen to autologous,  long-term cultured, 
antigen-reactive T cells or to a normal, HLA-DR-compatible, antigen-specific T  cell line. In 
contrast,  the patients'  EBV-B cells functioned normally as accessory cells for mitogen-induced 
T cell proliferation.  The results obtained from the investigations of MHC class II-dependent 
immune functions indicate antigen presentation by a subset of cells, obviously present in the 
HLA-DtL8 mRNA-expressing adherent MNC population,  whereas the patients'  EBV-B cells 
lack this ability. 
M 
HC class II proteins expressed on APCs play a critical 
role in cellular recognition, in antigen presentation, 
and in the induction of the immune response. In general, 
many different  peptides  derived  from naturally processed 
antigens bind to class II proteins and are then presented to 
helper T lymphocytes. MHC class II proteins are the product 
of immune response genes located on the short arm of chro- 
mosome 6  of the human genome (1). The class II locus 
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HLA-DR, -DQ, and -DP (2), and each isotype is encoded 
by separate ot and/~ chain genes. Conserved upstream sequence 
elements,  termed W,  X,  and Y,  and proteins that  interact 
with these boxes, have been shown to mediate B cell-specific 
and IFN-3,-induced expression of several HLA-D locus genes 
(3, 4). The HLA-D locus is unusual in that both chains of 
the various heterodimeric proteins are products of the same 
genetic region (1). Before being expressed on the cell surface, 
all MHC class II proteins are associated with the invariant 
chain (Ii) 1, and it has been proposed that this chain may di- 
rect class II proteins into the endocytic pathway, where they 
encounter internalized antigens (5). The level of cell surface 
expression of class II proteins correlates closely with the level 
of intracellular class II mRNA (3). Thus, modulation of MHC 
class II surface expression is generally achieved by regulation 
of class II gene expression.  Impaired expression of the HLA-D 
locus genes leads to a disease described as bare lymphocyte 
syndrome (BLS) (6). 
A number of studies have indicated that the HLA-D locus 
genes and their rearrangement  are intact in reported MHC 
class II-deficient patients and that regulatory mutations are 
responsible for the lack of stable mRNA (6-8). The regula- 
tory mutations involved affect class II expression at the tran- 
scriptional level (9). Analysis of MHC class II transcriptional 
mutant B cell lines that  were either derived from BLS pa- 
tients or produced in vitro has provided a clue to the role 
of c/s- and tram-acting regulatory factors. Fusion experiments 
of mutant cell lines to healthy B cell lines resulted in recon- 
stituted expression of all class II genes (3, 10-12). The same 
experiments carried out between various class II-negative B 
cell lines have defined four separate complementation groups, 
suggesting that multiple regulatory defects can cause this dis- 
ease (3,  10-12).  The consequences of all regulatory defects 
are the lack of RNA encoding  MHC class II molecules. 
In this paper, we present the molecular and immunolog- 
ical characterization  of a new phenotype of MHC class II 
deficiency in twin brothers. Flow cytometric analysis of their 
mononuclear cells (MNCs) and EBV-B cells isolated and es- 
tablished from peripheral blood of both children failed to de- 
tect class II antigen on the cell surface.  Therefore, we ana- 
lyzed transcription  and protein expression of MHC class II 
genes by reverse transcriptase (RT)-PCR and immunoblot- 
ting techniques.  Our results show an unusual mRNA pat- 
tern in the patients' MNCs and EBV-B cells (reduced or un- 
detectable mRNA levels of HLA-DR~, -DQ/3, and -DPc~, 
and normal mRNA levels encoding HLA-DRol, -DQc~, and 
-DPB). By fractionating MNCs into nonadherent (lymphoid 
cell population)  and adherent  cells (monocyte/macrophage 
lineage), an enrichment  of HLA-DIL/3 gene expression was 
found in cells of the adherent MNC fraction. Supporting the 
molecular results,  the patients'  T  cells  were capable of re- 
sponding  to recall  antigen  (tetanus  toxoid [Tet  Tox]) after 
1 Abbreviations used in this paper: BLS, bare lymphocyte syndrome; ~2m, 
B2-microglobulin; GAPDH, glyceraldehyde-3-phosphate  dehydrogenase; 
Ii, invariant chain; LF, Loeflter flocculation units; MNC, mononuclear 
cell; "let Tox, tetanus toxoid. 
vaccination.  In response to stimulation of the MNCs with 
recall antigen,  in both patients CD4 + and TCR-c~/B § cells 
were the major lymphocyte phenotype that became activated 
and expressed IL-2R (CD25). However, patients' EBV-B ceUs 
were not able to present antigen to autologous, long-term 
cultured,  antigen-reactive T  cells or to an HLA-DR-com- 
patible, antigen-specific T cell line from a healthy individual, 
whereas they functioned normally as accessory cells in the 
mitogen-response. These results indicate that cells within the 
monocyte/macrophage lineage, obviously present in the HLA- 
DRB mRNA-expressing adherent MNC population, are likely 
to be APCs in these two boys. In comparison to already known 
class II-deficient cell lines,  we describe here a new in vivo 
phenotype, suggesting the existence of a new complementa- 
tion group, and provide evidence for the functional equiva- 
lent  of the molecular characteristics. 
Materials and Methods 
Patients.  The children  are histoidentical  twin brothers  born 
prematurely at 34 wk of gestation to unrelated healthy parents of 
Turkish origin.  The boys had low birth weight  (KEN:  1,020 g, 
KER: 2,030 g), and were delivered by cesarian section because of 
premature rupture of membranes. The detailed clinical description 
of the two boys is reported elsewhere (13). One boy (KEN) was 
first admitted to the hospital at the age of 10 wk because of febrile 
seizures, and again with pneumonia at the age of 4 mo. Immuno- 
logical examination revealed  hypogammaglobulinemia, normal lym- 
phoproliferative responses to mitogens, and a normal distribution 
of lymphocyte subpopulations (CD3 + 62%, CD4 § 43%,  CD8 § 
23%, and CD19 + 27%). The diagnosis of MHC class II deficiency 
was based on flow cytometric  analysis, which revealed a lack of 
HLA-DR expression on the patient's resting peripheral blood leu- 
kocytes. The other boy (KER) was asymptomatic, and his physical 
and mental development was uneventful since birth. Immunolog- 
ical studies revealed a defect in MHC class II expression comparable 
with his twin brother,  whereas the distribution  of lymphocyte 
subsets (CD3 § 75%, CD4* 48%, CD8 § 29%, and CD19 § 14%) 
and the lymphoproliferative responses to mitogens were within the 
normal range. Serum IgG and IgA levels were normal, but serum 
IgM was decreased (20 mg/dl). 
Isolation of Mononuclear Ceils, Establishment of Lymphoblastoid B 
Cell Lines and Long-term Cultures ofT Cells.  MNCs were isolated 
from heparinized peripheral blood (7.5 IU/ml) by buoyant density 
gradient  centrifugation  (14, 15). After  enrichment  by multiple 
rounds of polystyrene adsorption, nonadherent cells were fraction- 
ated into T-enriched ceils and non-T cells by rosetting with sheep 
erythrocytes treated with AET (2-aminoethylisothiouronium  bro- 
mide; Sigma Chemical Co., St. Louis, MO) as described elsewhere 
(16). Non-T cells were transformed with EBV using the superna- 
tant from the B 95-8 marmoset call line (American Type Culture 
Collection, Rockville, MD) according to a standard protocol (17). 
Growing cells were expanded in RPMI 1640 medium supplemented 
with 20% heat-inactivated FCS (Hyclone Laboratories, Logan, UT), 
2 mM t-glutamine,  100 IU/ml penicillin, and 100/~g/ml strep- 
tomycin (Gibco, Paisley, Scotland). To establish an antigen-specific 
T cell line from a healthy, HLA-DR-compatible,  control individual 
or long-term cultured T cells from one (KEN) of the two patients, 
MNCs from the patient or the control were stimulated with Tet 
Tox for 1 wk and were then cultured for several  weeks in the presence 
of highly purified human Ib2 (10 IU/ml, Lymphocult T-HPLyo.- 
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(control individual) repeated restimulation using antigen and au- 
tologous macrophages. All cell cultures were maintained at 37~ 
in 5% COs humidified air. 
One.way Mixed Lymphocyte Reaction.  To examine MHC class 
I- and II-specific alloresponses in the patient KEN, MNCs from 
this patient or an unrelated healthy control individual were stimu- 
lated for 7 d with irradiated (10,000 tad) Dandi cells or EBV- 
transformed B cells from another unrelated patient with MHC class 
II deficiency  (BCH). Triplicate cultures of responder cells (2.5  x 
10S/ml) and stimulator cells (2.5  x  10S/ml) were set up in flat- 
bottomed microtiter plates (Falcon  3070, Microtest  III; Becton  Dick- 
inson Labware, Lincoln Park, NJ) in culture medium as previously 
described (18) supplemented with mouse ascites (1:50) containing 
irrelevant mAbs (control ascites) or mouse ascites containing the 
MHC class II-specific mAb 9-49 (kindly provided by Dr. K. F. 
Todd III, University of  Michigan Medical School, Ann Arbor, MI) 
(19) or MHC class I-specific mAb PA2.6 (kindly provided by Dr. 
J. L. Strominger, Harvard Medical  School, Boston, MA) (20). The 
resulting cell proliferation was assessed by [3H]thymidine incor- 
poration measured with a Tri-Carb liquid scintillation counter 
(model 4640; Packard Instruments,  Meriden, CT). 
B Cell Accessory  Cell  Function  for Recall  Antigen- and Mitogen-induced 
T  Cell Response.  To examine B cell accessory cell function for 
antigen- and mitogen-induced  T cell  proliferation,  a Tet Tox-specific 
T cell line from a healthy individual (HLA-DR compatible to the 
patients) or long-term cultured, antigen-reactive T cells from the 
patient KEN (2.5  x  10  S  T ceUs/ml) were stimulated for 3 d with 
Tet TOx (10 Loefl%r  flocculation units (LF)/ml; Swiss Serum and 
Vaccine Institute, Berne, Switzerland) or PWM (1:1,000, GIBCO 
BRL, Gaithersburg, MD) in the presence of autologous EBV-B 
ceils or HLA-DR-compatible  EBV-B cells from the patients or 
healthy control  individuals (2.5 x  10  s B cells/ml) as accessory 
cells. As a control, T cells were cocuhured with EBV-B cells in 
medium alone. Antigen- or mitogen-induced T cell proliferation 
was determined by measuring [3H]thymidine incorporation. 
Flow Cytometry.  Flow cytometric analysis  of surface membrane 
expression of MHC class I and II antigens and detection of in- 
tracytoplasmic expression of Ii was carried out by indirect im- 
munofluorescence using  the  mAbs Mon  1013 (clone 7.5.10.1, 
directed against HLA-DR, -DP, and -DQ; Monosan, Uden, The 
Netherlands) (21), IOT2 (clone B9.12.1, detecting a monomorphic 
determinant of MHC class I antigen associated with ~2-micro- 
globulin  (B2m); Immunotech,  Marseilles, France) (22), and 
VIC-Y1 (directed against Ii, kindly provided by Dr. O. Majdic, In- 
stitute of  Immunology, University  of  Vienna, Vienna, Austria) (23). 
Isotype-matched mouse monoclonal Ig was used as a control for 
unspecific staining. For intracytoplasmic staining, cells were fixed 
with 0.25% paraformaldehyde  and permeabilized  with 0.2% Tween 
in PBS. 
Surface expression of the Ib2R on CD3- or CD4-positive cells 
within the MNC fraction was examined  by dual-color flow cytom- 
etry after stimulation with antigen or mitogen. Therefore, MNCs 
(10Vml) were cultured in 24-well tissue culture plates for 7 d in 
the presence of antigen (Tet Tox, 10 LF/ml), mitogen  (PWM, 
1:1,000), or culture medium alone. Cells were stained using directly 
labeled mAbs Leu-4 (CD3), Leu-3a, (CD4), and IL-2R (anti-Tac, 
CD25) (all purchased from Becton Dickinson & Co., Mountain 
View, CA) and immunofluorescence staining was evaluated with 
a cytofluorograph (FACScan  |  Becton Dickinson & Co.). 
Isolation of RNA and Specific Amplification of cDNA.  Total  cel- 
lular RNA was isolated from nonstimulated MNCs and EBV- 
transformed B calls of the patients (KER, KEN) and healthy con- 
trois (HC,  MOTHER, FATHER) according to the method of 
Chomczynski (24). Equal amounts of total RNA, quantified at 
260 nm, were reverse transcribed into cDNA by first and second 
strand synthesis employing avian  myeloblastosis  virus (AMV) RT 
(Boehringer Mannheim Biochemicals, Mannheim, Germany). The 
cDNA was directly amplified (25, 26) on a thermocycler (model 
60; Biomed  Instruments Inc., Fullerton, CA) using AmpliTaq  DNA 
polymerase (Perkin Elmer Cetus, Norwalk, CT) and oligonucleo- 
tide primer pairs specific  for HLA-DRot (exonl, sense: ATGGCC- 
ATAAGTGGAGTCCCTGTGC;  exon4, antisense:  CCTGCGTTC- 
TGCTC~~GCACTCC)  (27), FILA-DRB1  (sense: 
GTCATTTCTTCAATGGGACGGAGCG,  antisense: CGCCGC- 
TGCACTGTGAAGCTCTC)  (28), FILA-DQo~  (KS151 and RS152), 
HLA-DQB (AmpA and AmpB), HLA-DPtx (AmpA and AmpB) 
(Genset, Paris, France), HLA-DPB1 (sense: CCTTGCAGCACC- 
ACAACCTGCTTGTC, antisense: CCTGTGCATGAAGATGCC- 
CACTCCAC) (29), HLA-Ii (sense: GGATGACCAGCGCGACCT- 
TATCTCC, antisense: CCAGATCCTGCTTGGTCACACCCAG) 
(30), B2m (sense: CTCGCGCTACTCTCTCTTTCTGG,  antisense: 
GCTTACATGTCTCGATCCCACTTAA)  (31), TNF-B and M-CSF 
(Clontech Lab., CA). Glyceraldehyde-3-phosphate  dehydrogenase 
(GAPDH) (sense: CCACCCATGGCAAATTCCATGGCA,  anti- 
sense: TCTAGACGGCAGGTCAGGTCCACC)  (32), and $14 ribo- 
somal protein  (sense: GGCAGACCGAGATGAATCCTCA,  an- 
tisense: CAGGTCCAGGGGTCTTGGTCC) (33) were used as 
internal controls. The amplification profile involved  30 cycles (35 
cycles for TNF-B and M-CSF) of denaturation at 95~  for 1 min, 
primer annealing at 60~  for 2 min (Genset primer pairs were an- 
nealed at 55~  and primer extension at 72~  for 3 rain. Aliquots 
of PCR-generated products were fractionated  on 1.5% EtBr-agarose 
gels, validated by the predicted size, and blotted onto Hybond-N 
filter membranes according to the manufacturer's protocol (Amer- 
sham International, Buckinghamshire, UK). 
Hybridization and Analysis of  Data by Densitometry.  Blotted filter 
membranes were validated by hybridization with internal probes. 
Therefore oligonucleotides specific for HLA-DRo~ (exon3: CCT- 
CAGT1GAGGC~AGGAAGGGGAGATAGTGG)  (27), HLA-DRB1 
(CTCCCCCACGTCGCTGTCGAAGCG)(28), HLA-DQcz (exon 
2,  KI-I54) (Genset), HLA-DQB (CTGGTAGTTGTGTCTGCA- 
CAC), HLA-DPo~  (Aso: AAGATGAGATGTICTATG  or AAGATG- 
AGCAGTTCTATG) (Genset), HLA-DP~I (CCAGCTCCCGTC- 
AATGTCTTACTCCG) (29), HLA-Ii chain (CAGGAGCCAATG- 
GTGCATCCAGCTCTC) (30), B2m  (CACTTTTTCAATTCT- 
CTCTCCATTCTTCAG) (31) and GAPDH (TCTAGACGGCAG- 
GTCAGGTCCACC) (32) were 3' end labeled using the enzyme 
terminal transferase (Boehringer Mannheim Biochemicals) and 
r  5'-triphosphate (Amersham International). 
The unincorporated  nucleotides  were removed  on an NAP-5 column 
(Pharmacia, Uppsala, Sweden). Prehybridization  of the filter mem- 
branes was carried out for 4 h at the corresponding annealing tem- 
perature (55-60~  in 5x  SSC, 20 mM NaPO4, pH 7, 10x  Den- 
hardt's solution, 7% SDS, 100 #g/ml sonicated  salmon sperm DNA, 
and 100/~g/ml poly(A). Hybridization was performed at 55-60~ 
in the prehybridization buffer containing 10% dextran sulphate 
plus added  radiolabeled-specific  oligonucleotides  for 16 h. The blots 
were washed once in 3x  SSC, 20 mM NaPO4 pH 7, 10x  Den- 
hardt's solution, 5% SDS for 30 min, followed by a second wash 
in lx  SSC, 1% SDS at hybridization temperature for 40 min. 
Air-dried filters were exposed to Kodak XDS films using Kodak 
X-OMATIC regular intensifying screens (Kodak, Rochester, NY). 
The relative  density of the fragments was determined by image- 
analyzing densitometry (OD*MM) (Pharmacia  LKB Biotech., pdi 
Quantity One, Uppsala, Sweden). The densitometric reading of 
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sponding  densitometric  reading  for  the  internal  controls  $14 
ribosomal protein  and/or GAPDH. 
Antibodies.  The anti-HLA-class II ~ chain mAbs DA6.147 (34) 
and 5F2.3 (35) were a generous gift of Dr. C. M. Steel (Western 
General Hospital, Edinburgh,  Scotland) and the anti-HLA-class II 
t~ chain mAb TAL-1B5  (36) was kindly provided by Dr. J. G. Bodmer 
(Imperial Cancer Research Fund, Lincoln's Inn Fields, London, UK). 
The anti-HLA-DIL8  mAb,  clone CR3/43,  was obtained  from 
Boehringer  Mannheim. 
Immunoblotting.  MNCs were lysed in lx  SDS sample buffer 
and boiled for 5 min before SDS-PAGE. EBV-B cells were lysed 
in NP-40 lysis buffer (20 mM Tris, pH 7.5, 150 mM NaC1, 1% 
NP-40, 0.5% deoxycholic acid, I mM PMSF, 10/~g/ml aprotinin, 
10 #g/ml leupeptin) and boiled for 5 min in 5 x SDS sample buffer 
or, alternatively, directly lysed and boiled in lx SDS sample buffer. 
After electrophoresis, gels were equilibrated in blotting buffer (48 
mM Tris, 39 mM glycine, 20% methanol) and proteins were trans- 
ferred to 0.2 #m nitrocellulose sheets (Schleicher and Schuell, Dassel, 
Germany) using a Trans-Blot SD semi-dry electrophoretic transfer 
cell (Bio-Rad Laboratories, Vienna, Austria).  The nitrocellulose 
sheets were blocked in 5% skim milk/TBS (Tris-buffered saline) 
containing 0.1% Tween-20, and then probed with the primary anti- 
bodies. Specific binding was visualized either by autoradiography 
at  -70~  using 3sS-labeled anti-mouse  Ig (0.2 #Ci/ml;  Amer- 
sham International)  and  Kodak  XAR films or with  the ECL 
Western blotting analysis system (Amersham International) in com- 
bination  with horseradish peroxidase-conjugated  anti-mouse Ig 
(Amersham International)  and Kodak XDS films. 
Results 
Lack of Class II Antigen Expression on EBV-B Cells from 
Patients with BLS.  Analysis of the patients' EBV-B cells by 
flow cytometric analysis revealed a lack of MHC class II an- 
tigens, whereas Ii chain and class I antigen expression was 
normal and comparable to a healthy control subject (Fig.  1, 
KEN, KER versus HC). Since the mAbs used do not distin- 
guish polymorphism  of class II molecules, it is likely that 
the observed lack of HLA-DR,  -DQ,  and -DP expression 
in both children reflected an absence of cell surface class II 
antigens, each consisting of distinct a  and ~/chains (Fig.  1). 
Uncoordinated Expression of el and fl Chain Genes of the 
HLA-D Region in the Patients.  Having demonstrated the lack 
of class II antigen on the surface of the MNCs and EBV-B 
cells  (Fig.  1) of the patients,  we examined class  II-specific 
gene expression.  Total RNA from the patients and from three 
healthy control individuals was subjected to RT-PCR anal- 
ysis.  The PCR-generated products  for the genes encoding 
HLA-DR, -DQ, and -DP c~ and B chains,  HLA-associated 
Ii chain, 32m, and GAPDH were detected by Southern blot- 
ting and specific hybridization under conditions in which no 
cross-hybridization occurs (for details see Materials and Meth- 
ods). As shown in Fig.  2, mRNAs encoding DRot, DQc~, 
and  DP/31 clearly accumulated  in  the  MNCs  and  EBV-B 
cells of the patients as well as the control subjects. However, 
no DtL3t-, DQ3-, or DPoe-specific  transcripts were seen in 
the EBV-B ceils, and very low levels could be detected in the 
MNCs of the patients (Fig. 2, KER and KEN). For accurate 
quantification,  we subjected the Southern blot-obtained signals 
to densitometric image analyzing. The densitometric readings 
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Figure  1.  Surface  membrane expression  of MHC class I and II antigens 
and intracytoplasmic expression  ofinvariant chain in EBV-transformed  pe- 
ripheral blood B cells. EBV-B  cells from both patients (KEN, KER) and 
a healthy, unrelated control (HC) were examined for surface membrane 
expression of MHC class I and II antigen and intracytoplasmic  expression 
of invariant chain, using indirect immunofluorescence  evaluated by flow 
cytometry. Results are depicted as fluorescence  intensity displayed on the 
horizontal axis (logarithmic scale) versus relative cell number given on 
the vertical axis. Black shading indicates staining with the specific  mAb, 
whereas broken lines indicate binding of an unspecific isotype-matched 
control mouse Ig. 
were normalized  to the expression of the constitutive con- 
trol mRNA encoding GAPDH. In agreement with the results 
shown in Fig. 2, DRBI-, DQ~/-, and DPot-specific mRNA 
could not be detected in the patients' EBV-B cells, whereas 
low levels were present in their MNCs (Fig.  3, b, d, and e). 
Control experiments demonstrated that mRNA expression 
of the Ii chain (Fig.  3 g) and expression of the B2m gene, 
which is associated with the class I molecule (Fig. 3 h), were 
normal  in all  individuals  tested. 
Presence and Distribution of  HLA-DR Proteins in Cellular Ly- 
sates of Class II-Deficient Patients.  To analyze in which way 
the defective transcription  of one of the chains specific for 
HLA-DR will affect translation of the observed mRNA (Fig. 
2), we examined  the occurrence of intracellular  HLA-DR 
proteins and Ii chain by immunoblotting techniques. As shown 
in  Fig.  4,  despite normal  mRNA  levels  strongly reduced 
amounts of HLA-DRa protein were found in the cellular 
lysates of EBV-B cells of both patients,  whereas,  as was to 
be expected, no HLA-DRB was detected in the same lysates, 
even after extensive exposure time. On the other hand, low 
levels of HLA-DR ot and/3 proteins were observed in the 
cellular lysates of patients' MNCs (Fig. 4). In agreement with 
the results obtained by flow cytometric analysis (Fig. 1), normal 
amounts  of Ii chain  were also found by immunoblotting 
(data not  shown). 
Enrichment of HLA-DRcr Protein in the Adherent Cell Popu- 
lation of One Patient Tested.  Since reduced amounts of HLA- 
A New Phenotype of Major Histocompatibility  Complex Class II Deficiency Figure 2.  Southern blot analysis of amplified cDNA from unstimu- 
lated MNCs and EBV-B calls. RNA from three healthy donors (HC, 
MOTHER, FATHER)  and two patients (KER, KEN) was isohted, reverse- 
transcribed, and amplified with the indicated specific  primer pairs (HLA- 
DRot, -DRBs, Inv. Chain, -DQa, -DQ3, -DPot, -DP31, B2m, and as in- 
ternal control, GAPDH) as described  in Materials and Methods. RT-PCR 
assayed without  cDNA template served as a negative control (NC). 
Amplified products were fractionated on 1.5% agarose  gels, blotted onto 
filter membranes, and hybridized  with internal probes (see Materials and 
Methods). 
DR oe and 3 proteins were present in MNC lysates, we wanted 
to identify the cells within the MNC fraction expressing HLA- 
DR molecules. Therefore,  MNCs from one patient  (KEN) 
were divided into nonadherent and adherent cell populations 
by polystyrene adsorption and the cell lysates were examined 
by immunoblotting.  In  good  agreement  with  the  results 
obtained from EBV-B cells,  a low level of HLA-DRoe pro- 
tein was found in the nonadherent cell population, consisting 
mainly of T  and B lymphocytes (Hg.  5).  However, HLA- 
DRoe strongly accumulated in the adherent cell population 
(Fig. 5). Image-analyzing densitometry of the depicted bands 
revealed  a nearly fourfold increase of HLA-DR~ in the ad- 
herent cells, reaching 42% of the protein level present in the 
same cell population of a healthy control. Because of the small 
number of MNCs available from our patient and the consti- 
tutively lower amount of HLA-DRfl present in all cells ex- 
pressing MHC class II molecules, we were unable to detect 
HLA-DRfl by immunoblotting  in either  the nonadherent 
or the adherent cells. However, the observed increase of HLA- 
DRc, protein in the adherent cell population, together with 
our mRNA data presented in Fig. 6,  strongly suggest that 
the cells expressing both ~  and 3  chains are a subset of the 
monocyte/macrophage  lineage. 
1415  Hauber  et al. 
HLA-DR  rnRNA Expression  in the Monocyte/Macrophage 
Lineage of One Patient Tested.  Here we investigated  the origin 
of the  HLA-DRB1  message  of one  patient's  MNCs  after 
separating the nonadherent cells from the adherent cell popu- 
lations by multiple rounds of polystyrene adsorption.  Total 
RNA was isolated from the various cell fractions and sub- 
jected to RT-PCR analysis. Our results show that the mRNA 
specific  for HLA-DR31  was enriched  in  the  adherent  cell 
fraction as compared to the mRNA seen in the nonadherent 
cells, whereas EBV-B cells of the same patient lacked any de- 
tectable HLA-DIk31-specific mRNA  (Fig.  6 a). 
To demonstrate  that  the  HLA-DRBi-specific transcript 
seen in the adherent cell population originates from a mono- 
cyte/macrophage lineage,  we investigated the expression pat- 
tern of the cytokines TNF-B and  M-CSF in the same cell 
fractions.  Whereas  TNF-3 was constitutively produced by 
human EBV-B ceils, the cytokine M-CSF was dearly increased 
in adherence-activated macrophages.  As shown in Fig. 6 b, 
no TNF-3 message, indicative of the presence of lymphoid 
cells, was found in the adherent cell fraction.  However, mRNA 
encoding M-CSF could easily be detected (Fig.  6 c). These 
findings indicate that  the HLA-DK~1 gene expression ob- 
served in the MNCs of the patient  is derived from cells of 
the monocyte/macrophage  lineage. 
Patients' CD4 + T  Cells Respond to Recall Antigen.  Flow 
cytometric analysis of peripheral blood MNCs after antigenic 
stimulation  was carried out to investigate whether  the pa- 
tients' T cells are capable of responding to recall antigen (Tet 
TOx), and to examine the phenotype of the antigen-responsive 
cells. MNCs were stimulated with Tet Tox for 7 d, and the 
expression of IL-2K (CD25) on activated lymphocyte sub- 
populations was then assessed by dual-color flow cytometry. 
The results depicted in Fig.  7 demonstrate  that  despite the 
fact that  the patients'  MNCs lack detectable MHC class II 
antigen on the cell surface,  their T  cells responded to recall 
antigen.  In  two previously vaccinated controls  (HC  1 and 
HC 2) tested in parallel  as well as in our two patients,  the 
majority  of activated  cells  after  Tet  Tox stimulation  were 
CD3 § T  cells [(percent CD25 §  CD3 + cells:  controls,  HC1 
21.5, HC2 37.3; patients, KEN 42.4, KEK 24.9; Fig. 7) (per- 
cent CD25+CD3 -  cells: controls, HC1 5.7, HC2 17.4;  pa- 
tients, KEN 8.1, KER 9.9; Fig. 7)].  However, the patients' 
IL-2K-expressing T  cells activated in response to antigenic 
stimulation were still negative for HLA-DR (data not shown). 
In antigen-stimulated  cell cultures of controls and patients, 
a significant  subset of the activated T cells expressed the CD4 
phenotype, even though the portion of CD4-  activated cells 
appeared to be higher in the patients' cell cultures [(percent 
CD25§  §  cells:  controls,  HC1  17.0,  HC2  32.8;  pa- 
tients,  KEN 23.4, KER 15.1) (percent CD25+CD4 -  cells: 
controls,  HC1 5.1, HC2 8.1; patients,  KEN 25.0, KER 14.8)]. 
In  addition,  the majority of the  activated cells  within  the 
antigen-stimulated  MNC cultures expressed the TCR-od3 
complex in the patients as well as in the controls (data not 
shown). 
Patients'  EBV-B  Cells  Are  Unable  to  Present Recall  An- 
tigen.  The above described findings dearly demonstrate that 
CD4 §  T  cells  become  activated  and  express  IL-2R  after Figure  3.  Densitometric  quantifica- 
tion  of HLA-DRc~  (a), -DRB1  (b), 
-DQa (c), -DOff (d), -DPc~ (e),-DVfll 
(J), invariant chain (g), and fl2-micro- 
globulin (h) signals obtained from pa- 
tients'  and  controls'  unstimulated 
MNCs and EBV-B cells. The relative 
density  of"  the  signal obtained  by 
Southern  blot  analysis of the  PCR- 
generated products (depicted in Fig. 2) 
was measured by image-analyzing den- 
sitometry.  In  both  patients  (KER, 
KEN) and three healthy control indi- 
viduals (HC, MOTHER, FATHER) 
the densitometric reading of each assay 
was related to the corresponding  den- 
sitometric reading of the internal con- 
trol GADPH. Relative levels of mRNA 
are presented as optical density  x  mm 
[OD'MMI. 
stimulation of the patients' MNCs with recall antigen. This 
observation indicates that cells within the MNC population 
must be capable of presenting recall antigen in the context 
of MHC class II molecules. In addition to cells of the mono- 
cyte/macrophage lineage and dendritic cells, B cells have the 
capacity to act as APCs. To investigate whether B cells func- 
tioned as APCs in inducing T cell responses to recall antigen 
in the two boys, we examined the antigen-presenting capacity 
of the patients' EBV-B  cells. The results presented in Table 
1 demonstrate that in contrast to healthy controls, the EBV- 
B cells from both patients were unable to induce antigen- 
specific stimulation of a normal, HLA-DK4-restricted (i.e., 
HLA-DR compatible to the patients). Tet Tox-specific T cell 
line, whereas the patients' EBV-B cells behaved normally with 
respect to accessory cell function for PWM-induced T  cell 
proliferation. In addition, the EBV-B cells from one patient 
tested were unable to present antigen (Tet Tox)  to autolo- 
gous, long-term cultured, antigen-reactive T  cells (data not 
shown). 
Lympkocytes  from One Patient Tested  Mount an MHC Class I- 
1416  A New Phenotype  of Major Histocompatibility  Complex  Class II Deficiency Figure  4.  Occurrence of HLA-DK ot and/~ proteins in whole lysates 
of EBV-B cells and MNCs. Cell lysates from two patients (KEN, KER) 
and a healthy control (HC) were separated  by SDS-PAGE  and the proteins 
were transferred onto nitrocellulose sheets. The separated proteins were 
probed with  a pool of three  monodonal  anti-HI,A-DR o~ antibodies 
(DA6.147, 5F2.3, and TAblB5) (/eft  lanes), or with a B chain-specific  mono- 
donal  anti-HLA-DR  antibody  CR3/43  (right lanes). 3sS-conjugated 
anti-mouse Ig was used as a secondary antibody and the x-ray film was 
exposed for 14 d at  -70~  Molecular weights in kD are indicated on 
the right. 
and II-specific Alloresponse, which Can Be Inhibited by mAbs. 
MHC  class I- and II-specific alloresponses have been exam- 
ined in one patient (KEN) in a one-way mixed lymphocyte 
reaction (MLR), applying irradiated Daudi cells (MHC class 
II  +, MHC class I-) and irra~ated EBV-B cells from another 
class  II-deficient  patient  ([BCH]  MHC  class  II-,  MHC 
class  I +)  as  stimulator  cells.  The  data  depicted  in  Table 
2 show that MNCs from our patient responded to both al- 
logeneic class I and II antigens, although alloresponse to MHC 
class I was lower than in the control (the patient's responder 
cells and the BCH-stimulator  cells shared one class I deter- 
minant, HLA-A2). The patient's cellular response to MHC 
class II antigens could be inhibited by adding the mAb 9-49 
to the system, known to block class II-specific alloresponses 
Figure  5.  Distribution  of 
HLA-DK o~ protein in adherent 
and nonadherent cell populations. 
MNCs of one patient (KEN) and 
a healthy control (HC) were ffac- 
tinnated  into  nonadherent  (left 
lanes) and  adherent  ceils (right 
lanes) by polystyrene adsorption. 
Cell  lysates were  separated by 
SDS-PAGE and transferred onto 
nitrocellulose as described and the 
proteins  were probed  with  the 
anti-HLA-DR  oe  mAb  pool. 
Specific binding  was  visualized 
with horseradish peroxidase--conjugated  anti-mouse Ig in combination  with 
the ECL Western blotting detection system. Molecular weights in kD 
are indicated on the right. 
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Figure  6.  Densitometric quantification of Southern blots analyzed for 
amplified cDNAs encoding HLA-DR~I (a), TNF-/3 (b), and M-CSF (c). 
Total RNA of the indicated cells from one class II--ddieient patient (KEN) 
and a healthy control individual (MOTHER) was isolated and analyzed 
by RT-PCR as described in Materials and Methods. The amplified  prod- 
ucts were fractionated on 1.5% agarose gels and the corresponding bands 
were quantified by image-analyzing densitometry. In each lane the den- 
sitometric reading of HLA-DRB1, TNF-B, and M-CSF was related to the 
corresponding reading for the control ribosomal protein $14 which was 
coamplified in each reaction. In a, the relative DRB1 mRNA levels in 
the patient's cells are presented as percentage  of his mother's levels  (100%). 
In b and c, the relative  levels  of TNF-B and M-CSF are presented as optical 
density x mm [OD*MM]. RNA derived  from the T-enriched  cells, elutri- 
ated macropbages, and MNCs of two Red Cross healthy donors served 
as assay controls in b and c (open boxes). 
(19).  Addition  of the MHC  class I-specific mAb PA2.6  in- 
hibited MHC class I-specific allostimulation, whereas it had 
no  effect on  MHC  class  II. 
Discussion 
MHC  class II antigens  are expressed on B  cells and cells 
of the monocyte/macrophage lineage  and  are inducible  on 
many other cell types by certain cytokines such as IFN-~/and 
IL-4 (3).  Defective MHC  class II surface expression as well 
as the absence of the respective mRNA  characterize a genetic 
disease  known  as  BLS.  The  diagnosis  of BLS  in  the  twin HC  1 
HC 2 
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Figure  7.  Peripheral  blood 
MNCs  from the patients  (KEN, 
KER) and unrelated  healthy  con- 
trols (HC I, HC 2) were cultured 
for 7 d in RPMI 1640 medium with 
or without tetanus toxoid (Tet Tox, 
10 LF/ml). After activation, the sur- 
face expression of CD25 on CD3 + 
and CD4 + cells was examined by 
dual-color  flow cytometry,  as de- 
scribed in Materials and Methods. 
brothers presented in this study was based on flow cytometric 
analysis ofMNCs. FACS  |  analysis of their EBV-B cells failed 
to detect MHC dass II antigens, whereas class I and Ii chain 
surface expression was comparable to the controls. Since the 
antibodies used recognize monomorphic  dass II determinants, 
the observed lack of HLA-DR, -DQ, and -DP surface ex- 
pression  in the patients'  EBV-B cells most likely reflects an 
actual absence  of all class II molecules. Similar  results have 
been reported from other laboratories  on cell lines derived 
from MHC class II-deficient patients as well as on laboratory- 
mutant cell lines (12). 
Whereas  IFN-T treatment could not restore  class II ex- 
Table  1.  Patients'  EBV-B Cells Function Normally as Accessory Cells for Mitogen-induced T  Cell Proliferation, but Are Unable to 
Present Recall Antigen  to a Normal HLA-DR-restricted,  Antigen-specific T  Cell Line 
EBV-B cells  HLA-DR typing  Medium  Tet  Tox  PWM 
-  112  _+  60  117  +  141  106  _+  42 
Autologous control  4  854  _+  130  16,854  _+  720  40,326  _+  602 
HLA-DR compatible controls 
HWG  4  487  _+  11  19,977  _+  1,802  - 
MYD  4  3,419  _+  292  62,975  _+  4,569  58,962  _+  3,280 
HWE  4,7  1,680  _+  38  36,649  _+  3,554  18,824  _+  3,275 
DE  4,7  3,593  _+  218  28,730  _+  6,310  - 
Patient  KEN  (HLA-DR compatible)  2,4  593  _+  91  437  _+  24  41,390  _+  3,604 
Patient  KER (HLA-DR compatible)  2,4  618  _+  220  622  +  266  42,872  +  3,837 
To examine B cell accessory cell function  for antigen- and mitogen-induced  T cell proliferation,  a Tet Tox-specific  normal T cell line (2.5  x  105/ml) 
was stimulated for 3 d with Tet Tox (10 LF/ml) or PWM (1:1,000) in the presence of autologous  or HLA-DR-compatible EBV-B cells from control 
individuals or the patients  (2.5  x  10S/ml). As a control, T cells were cocultured with EBV-B cells in medium alone. Antigen- or mitogen-induced 
T cell proliferation  was determined  by measuring  [3H]thymidine  incorporation and results are expressed as dpm [3H]thymidine  uptake (mean  +  SD 
of triplicate  cultures). 
1418  A New Phenotype  of Major  Histocompatibility Complex Class II Deficiency Table  2.  Patients'  T  Cells Mount an MHC Class I- and II-specific AUorestmnse 
Stimulus 
Proliferative Response of MNCs ([3H]thymidine incorporation, 
dpm,  mean _+  SD of triplicate cultures) 
Control  Patient KEN 
Medium 
Daudi  +  control ascites 
Daudi  +  9-49 (MHC class II) 
Daudi  +  PA2.6 (MHC class I) 
BCH-B  +  control ascites 
BCH-B  +  9-49 (MHC class II) 
BCH-B  +  PA2.6 (MHC class I) 
505  •  251  153  +_  19 
31,343  _+  12,242  34,978  _+  7,078 
3,154  •  521  6,697  _+  2,545 
nt  22,523  _+  4,796 
103,518  •  16,426  9,399  _+  591 
93,022  •  20,290  10,072  •  390 
nt  969  •  472 
MHC class I- and lI-specilic alloresponses  were examined  by coculturing  MNCs from patient KEN or a healthy, unrelated  control with irradiated 
Daudi cells or EBV-B cells from another class II-deficient  patient BCH for 7 d in the presence of control mouse ascites (diluted 1:50 in medium) 
as a source of irrelevant mouse mAbs, mouse ascites containing the MHC class II-specific mAb 9-49, or the MHC class I-specific mAb PA2.6. 
MNCs cultured without Daudi cells were included  as a control. Background  [3H]thymidine  uptake of irradiated Dandi cells was 1,104 + 420 dpm 
(medium control) and 1,136 _+ 758 dpm after  cultivation  in the presence of PWM, background  [3H]thymidine  uptake of BCH-B cells was 869 •  73 
and 449 •  109, respectively. 
pression  in most BLS patients' B call lines  (6,  9,  37,  38), 
IL-4 was able to enhance class II antigen expression  on B 
and T cells of MHC class II-deficient CID patients (39, 40). 
Though IFN-~ and IL-4 are strong inducers of class II genes 
in a variety of cells, neither cytokine was able to restore class 
II-specific mRNA levels in our patients' EBV-B cells (data 
not shown). 
Analysis of the transcription of HLA-D locus genes  by 
RT-PCR revealed an uncoordinated expression  of the class 
II isotype ol and fl chains in the EBV-B cells derived from 
the twin brothers. Whereas HLA-DRoe, -DQol, and -DP3 
chain-specific transcripts were readily detected, no message 
was observed for HLA-DR3, -DQ3, or -DPoe. Only after 
extremely extended exposure time, was a faint signal for HLA- 
DQ~ observed.  Importantly, gene expression of the Ii chain 
was normal or even increased in both patients' EBV-B cells. 
Furthermore, proteins for HLA-DRo~ and the Ii chain were 
present as visualized by immunoblotting of cell lysates, indi- 
cating that the observed transcripts were functional and that 
a translational defect could be ruled out. The uncoordinated 
expression of the class II isotype o~ and/~ chains detected differs 
from all other published results concerning regulation of 
HLA-D locus genes. Four levels of regulation have been charac- 
terized on the basis of the defects  observed  in MHC class 
II gene expression.  Level one comprises cells from BLS pa- 
tients responsive to cytokine treatment (3). The second level 
of gene regulation involves combined class II and Ii chain 
expression, as illustrated by defects in class II-negative mouse 
mutants (41). A third level includes defective expression  of 
all HLA-D locus genes, whereas expression  of the Ii chain 
is not affected, as described for several MHC class II-negative 
patients (9),  for the EBV-B  cell lines BLS-2 and BCH (8, 
12), and for the laboratory mutants RJ2.2.5 and 6.1.6  (12, 
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42).  The fourth and last level concerns rare cases with dis- 
sociation in gene regulation of the class II isotypes. DePreval 
et al. (9) reported a class II-deficient, patient-derived B cell 
line expressing low amounts of HLA-DR oe and 3  chain- 
specific mRNA, whereas the other two isotypes were ab- 
sent. This mRNA pattern (DRc~ +3 +, DQ-, DP-) distin- 
guishes this B cell line from other class II-negative patients 
tested (9). Furthermore, a subclone of a human erythroleu- 
kemia cell line (HEL-DR +) expressing HLA-DR and -DP, 
but no -DQ mRNA, has been described (43).  In another 
BLS patient-derived B cell line (BLS-1) a very low level of 
HLA-DQol mRNA was present, whereas -DR,  -DP,  and 
-DOff transcripts were not detected (8). Although the defect 
seen in our patients' EBV-B cells is closest to the fourth level 
with heterogeneous defects in gene regulation (DKee +3-, 
DQoe~fl - , DPol-fl+), their class II isotype mRNA pattern 
dearly distinguishes them from other members of that group, 
e.g., HEL-DR + cells (DRoe+3 +  , DQ-, DPoe+), BLS-1 cells 
(DR-, DQol §  DP-), and the laboratory mutant clone 
13 (DR-,  DQo~+3 +,  DP-)  (7, 8,  37). 
Fusion experiments between different class II-defective cell 
lines from BLS patients and laboratory mutant cell lines have 
shown that genetic defects in trans-activating factors can lead 
to a failure in transcription and expression  of class II genes 
(3,  12). Because of these fusion experiments, complementa- 
tion groups were defined: most class II-negative patients' B 
cell lines (DR-,  DQ-,  DP-)  and the BLS-1 cell line (de- 
scribed above) belong to complementation group I. Binding 
of a protein (KF-X) to the X box sequences on the HLA- 
DKoe promotor was deficient in the cells of this group I (44). 
Whereas nearly all members (RJ2.2.5,  BLS-2,  BCH, etc.) 
of the complementation group II did not express any of the 
HLA-D locus genes, clone 13 was negative for DR and DP, but does express DQ. Benichou et al. (12) suggested that the 
cell lines  of this group  II lack the activity of a gene that 
can differentially regulate DR/DP and DQ promotors (12). 
Steimle et al.  (45) identified a splicing mutation in a gene 
coding for a tram-activator protein (CIITA) necessary for MHC 
class II expression. CIITA is responsible for the class II regula- 
tory defect in the cell lines of the patients and mutants be- 
longing to complementation group II (38, 45).  The defects 
responsible for the complete lack of class II gene expression 
in cell lines belonging to complementation groups III (6.1.6) 
and IV (SJO and TF) are still unknown. The differential ex- 
pression of ol and fl chains of the individual HLA-isotypes 
observed in our patients' EBV-B cells differs from all other 
B cell lines of class II-deficient patients and laboratory mu- 
tants described. The results clearly demonstrate an uncoor- 
dinated expression of HLA-D locus genes and reflect regula- 
tory mechanisms unrecognized up  to  now.  We therefore 
suggest the existence of a new level of regulation of the MHC 
class II molecules. It cannot be differentiated whether the 
regulatory mechanism is chain specific or represents a coor- 
dinated regulation of several chains,  e.g., DR3, DQfl, and 
DPol. However, the results indicate that the B cells of our 
patients represent a new complementation group. 
Whereas no message for DR3,  DQ3,  or DPcr could be 
observed in the patients' EBV-B cells, trace amounts of specific 
mRNA were found in their MNCs. Gene expression of  DRoe, 
DQc~, and DPfl was normal in the MNCs as well. Quanti- 
fication revealed that in one patient's MNCs (KER) 7-8% 
and in the other patient (KEN) 3-6%  of the mRNAs en- 
coding HLA-DR3, -DQ3, and -DPa were detectable. More- 
over, the trace amounts of mRNA found in both patients' 
MNCs were confirmed by the detection of protein for HLA- 
DR.fl. These results indicate that regulation of the class II 
genes vary depending on the cell type. 
Class II-expressing cells were further characterized by frac- 
tionating MNCs from one child (KEN) and his mother into 
nonadherent and adherent cells. We analyzed the expression 
of the HLA-D locus gene DRB found to be defective in the 
patients'  EBV-B  cells.  Interestingly,  HLA-DRB-specific 
mRNA could be detected in the adherent cell population in 
about half of the quantity (57%) expressed by cells of the 
mother. To further characterize these cells, we examined the 
expression pattern of  certain cell-specific cytokines, e.g., TNF-3 
and M-CSF.  Whereas TNF-3 is predominantly a product 
of lymphocytes and constitutively produced by human EBV-B 
cell lines, M-CSF is strongly expressed by macrophages, es- 
pecially after activation by adherence to plastic and during 
differentiation (46). As expected, TNF-3 mRNA levels were 
high in EBV-B cells and in the nonadherent fraction, indica- 
tive of an enrichment of lymphoid cells. Whereas no tran- 
scripts for TNF-3 were detectable in the adherent cell frac- 
tion,  the M-CSF  mRNA level was increased, confirming 
enrichment of cells of the monocyte/macrophage lineage. 
These results indicate that HLA-DR-expressing cells are ob- 
viously cells of the monocyte/macrophage lineage present in 
the adherent cell fraction of the patients' MNCs. This finding 
supports the assumption of a "fine tuning" of the regulatory 
mechanisms of the MHC class II genes (3,  47). 
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MHC class II molecules play a key role in the regulation 
of antigen-induced immune responses due to their pivotal 
role in antigen presentation. Peptides bound to class II mole- 
cules on the surface of APC are the ligand for specific TCRs 
on CD4 + T  cells (48).  In addition,  class II expression on 
thymic epithelial cells is critical for the generation of mature 
CD4 + T  cells (49).  The majority of previously described 
MHC class II-deficient patients showed a marked reduction 
in peripheral blood  CD4 + T  cell  counts (50).  The CD4 
lymphopenia was independent of the clinical  status of the 
patients, and thus appeared to be in consequence of MHC 
class II deficiency (51). A similar reduction or complete ab- 
sence of CD4 + T  cells in the periphery has been found in 
MHC class II-deficient mice that lacked cell surface expres- 
sion of class II molecules due to disruption of the class II 
gene in embryonic stem cells (52, 53). Treatment of the mice 
with MHC class II-specific antibody in vivo prevented the 
differentiation of immature thymocytes into mature CD4 +, 
CDS-  T  cells (54). 
The two boys described here lacked MHC class II antigen 
on the surface of their peripheral blood leukocytes, but in 
contrast  to  previously described patients,  presented with 
normal numbers of CD4 + T cells in the periphery (13, 50). 
Furthermore, specific antibodies were found after vaccination 
in vivo (13). In agreement with the patients' observed anti- 
body response, the present study shows that CD3 + T cells 
became activated and expressed IL-2R (CD25) in response 
to  stimulation  of MNCs  with  recall  antigen  (Tet  Tox). 
CD4 § TCR-o~/fl + cells were the major activated phenotype 
within these T  cell populations. 
The results seen on the transcriptional level in the two pa- 
tients clearly indicated that regulation of MHC class II ex- 
pression was different in nonadherent cells (e.g., B cells) com- 
pared to a subpopulation of cells observed in the adherent 
MNC fraction. Further investigations showed that the pa- 
tients' B cells were also different from other APCs (e.g., mono- 
cytes, macrophages, dendritic cells) with respect to their ca- 
pacity to present recall antigen, which is known to require 
functional MHC class II molecules. Whereas APCs present 
within the boys' MNC population were capable of inducing 
antigen-specific activation of CD4 + T  cells,  our patients' 
EBV-transformed B cells were unable to function as APCs 
in the activation of autologous antigen-reactive T  cells or 
a normal, HLA-DR-compatible, antigen-specific T cell line 
derived from a healthy individual. The data show that cells 
contained within the MNCs other than B cells function as 
APCs in inducing recall antigen-specific T cell responses in 
the two boys. Supporting these data, a subpopulation of cells 
acting as APCs within the adherent MNC fraction, but not 
patients' B cells, expressed DRf-specific mRNA and DRc~ 
protein. 
Although expression of MHC class II molecules on the 
surface of the patients' MNCs was not detected by flow cytom- 
etry, cells of the monocyte/macrophage lineage might still 
express very low levels of class II antigens on their surface, 
sufficient to stimulate antigen-reactive CD4 + T  cells. In ac- 
cordance with this hypothesis, it is known that expression 
of very low numbers of antigen/MHC class II complexes 
A New Phenotype of Major Histocompatibility Complex Class II Deficiency on  an  APC,  probably  as  few as  200-300  complexes,  are 
suificient to stimulate  a T  cell (55). 
In a previous study, we found that T cells from a patient 
with MHC class II deficiency were able to respond to class 
I alloantigens, but failed to recognize allogeneic MHC class 
II determinants.  The lack of the MHC class II-specific T 
cell repertoire was accompanied by a substantially decreased 
number of circulating  CD4 + lymphocytes (56).  Although 
this has not been examined directly, both fndings might have 
been due to defective expression of MHC class  II antigen 
on thymic epithelial  cells. 
In contrast, T  cells tested in one of the two patients de- 
scribed in the present paper could respond to MHC class I 
and II aUostimulation, and this response could be inhibited 
by mAbs of the respective specificity.  Compared to the pre- 
viously described patient by Mannhalter  et al.  (56),  the T 
cells of the patient examined in this study were capable of 
recognizing both MHC class I and II antigens. Whereas di- 
rect examination of MHC class II expression in the thymus 
of the two boys is not possible, a normal class II-specific T 
cell response might be due to a residual expression of class 
II antigens in the thymus, which also enabled the matura- 
tion of normal numbers of CD4 + T  cells as present in our 
patient. 
On the basis of the above considerations,  it is tempting 
to speculate that B cells  and monocytes/macrophages  may 
acquire the capacity to regulate class II genes in a distinct 
fashion, pointing to cell type-specific factors involved in regula- 
tory pathways of the class II molecules. In this sense, the bio- 
logical role of MHC class II antigens should not only be seen 
within their structural characteristics, but also in the context 
of a developmentally controlled program  of differentiation 
of various cell types. 
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